|
About the Confirmatory Testing category -Please read before posting
|
|
1
|
737
|
March 30, 2025
|
|
A Rapid and Sensitive LC–MS/MS Method for Quantification of NDSRI in Melatonin Drug Product via Controlled In Situ Formation-Pub
|
|
0
|
12
|
August 14, 2026
|
|
N-Nitroso Metamizole Impurity C
|
|
5
|
483
|
August 11, 2026
|
|
An Analytical Quality by Design-guided method development for the quantification of N-nitroso-fluoxetine to support mitigation strategies for a fluoxetine drug product-Pub
|
|
2
|
198
|
August 8, 2026
|
|
N Nitroso Tadalfil
|
|
19
|
1379
|
August 7, 2026
|
|
Nitrosamine Control Strategy for Products within the Scope of ICH S9
|
|
5
|
296
|
August 7, 2026
|
|
Qualitative & Quantitative Analysis of Nitrosamines by FTIR
|
|
6
|
225
|
August 6, 2026
|
|
Determination of Trace Nitrosamines in Plastic Pharmaceutical Packaging Materials
|
|
2
|
159
|
August 4, 2026
|
|
N-Nitroso meglumine
|
|
34
|
2877
|
August 1, 2026
|
|
N-Nitroso Desmethyl Tramadol - Standard
|
|
3
|
215
|
July 27, 2026
|
|
Nitrosamines: Mass Spectrometry-Based Analytical Procedures Criterias
|
|
12
|
4674
|
July 25, 2026
|
|
N-nitrosoproline
|
|
0
|
109
|
July 20, 2026
|
|
Determining Low PPB Levels of Nitrite in Polymeric Excipients
|
|
2
|
407
|
July 19, 2026
|
|
Trace-level LC–MS/MS quantification of two nitrosamine impurities formed from terazosin-related impurities in pharmaceutical products and greenness assessment-Pub
|
|
2
|
202
|
July 15, 2026
|
|
N-nitroso-Furosemide
|
|
4
|
727
|
July 6, 2026
|
|
N-Nitroso Desethyl Amiodarone in Amiodarone HCl Tablets by LC-MS/MS Metodu
|
|
5
|
295
|
July 6, 2026
|
|
NDBA interference on Parecoxib testing?
|
|
3
|
164
|
June 23, 2026
|
|
A Robust and Universal LC–MS/MS Method for Determination of N-Nitrosodimethylamine in Pharmaceuticals Using a C30 Column -Pub
|
|
1
|
205
|
June 22, 2026
|
|
N-Nitroso Vonoprazan impurity peak area variation observed during drug product analysis by LCMS
|
|
1
|
157
|
June 8, 2026
|
|
MS Method Development Criterias?
|
|
1
|
176
|
June 2, 2026
|
|
EDTA-Related Nitrosamine Impurities: Two Critical Pain Points in Pharma R&D
|
|
5
|
491
|
June 1, 2026
|
|
Understanding In Vitro Nitrosamine Formation During Sample Preparation
|
|
4
|
306
|
June 1, 2026
|
|
Solution stability of NDSRI
|
|
8
|
411
|
May 25, 2026
|
|
Development and Validation of a Trace-Level LC–MS/MS Method for the Determination of N-Nitroso Clozapine in Clozapine Drug Substance -Pub
|
|
0
|
113
|
May 20, 2026
|
|
Strategies for Mitigating In-Source Fragmentation in NDSRI Analysis using LC-MS
|
|
4
|
2966
|
May 20, 2026
|
|
UHPLC-MS/MS Single Run Quantification Method for Simultaneous Determination of Triazolopyrazine and N-Nitroso-Triazolopyrazine in Sitagliptin; Risk Assessment, Scavenger-Based Mitigation, and Stress Stability Study -Pub
|
|
0
|
104
|
May 20, 2026
|
|
Liquid Chromatography–High-Resolution Mass Spectrometric Determination of Nitrite Ion Concentration in the Natural Water Resources -Pub
|
|
0
|
91
|
May 20, 2026
|
|
Simultaneous Determination of Duloxetine and N-Nitroso-Duloxetine in Reactor Cleaning Solvent Samples by LC–HRMS: Formation, Quantitation, and Green -Pub
|
|
0
|
136
|
May 20, 2026
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
13
|
1245
|
May 18, 2026
|
|
Diluent Selection for Nitrosamine Impurities
|
|
7
|
404
|
May 8, 2026
|